Bayer AG

Explore how Bayer AG’s earnings beat and FDA priority‑review of its stroke‑prevention drug BAY‑S12 are driving market gains and promising earlier, cost‑effective stroke care.

Explore how Bayer AG’s new shareholder ID updates, treasury share cuts, and AI‑powered commercial talks reveal its sharp focus on governance, capital efficiency, and digital strategy.

Explore how Bayer AG’s Crop Science unit drives 2026 growth, from gene‑edited crops to AI irrigation, while boosting yields and community impact.

Explore Bayer AG’s Q1 2026 results: Crop Science’s €3.1bn revenue surge, Pharma’s patent‑cliff strategy, and a €7bn legal settlement’s impact on earnings.

Read how Bayer’s shares slipped ahead of a U.S. glyphosate trial, with investors weighing potential settlements and the broader market’s geopolitical backdrop.

How the Supreme Court’s Roundup ruling could cost Bayer AG $3‑$5 bn, shift agro‑chemical regulation and raise healthcare supply‑chain costs.

How Bayer’s new dividend policy, legal updates, and board changes could shape its future—and what that means for investors

Explore Bayer AG’s AGM plans: debt‑reduction goals, margin boost, new governance, and a modest dividend strategy aimed at long‑term R&D growth.

Explore how Bayer AG’s Supreme Court case and board reshuffle could reshape healthcare delivery—impacting reimbursement, supply chains, and patient access.

Explore how Bayer AG’s 4% dip in Spanish sales and 20% hit to agriculture stem from Movento’s EU withdrawal, revealing impacts on crop protection and regulatory shifts.